Walpar Nutritions Ltd (WALPAR) — shareholding pattern, promoter holding, financials and share price
About Walpar Nutritions Ltd (WALPAR)
Walpar Nutritions Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as WALPAR and on the BSE under scrip code 535385. Its ISIN is INE0G2G01015.
Incorporated in 2009, Walpar Nutrition Ltd develops and manufactures various pharmaceutical products. [1]
Walpar Nutritions Limited is engaged in the manufacturing, marketing, and trading of pharmaceuticals, nutraceuticals, herbal, and Ayurvedic products both online and offline.
The company evolved from a partnership firm into a public limited company with roots dating back to 2009, emphasizing its strong foundation in the nutraceutical domain.
Listed peers in Pharmaceuticals: JFL Life Sciences Ltd, Parmax Pharma Ltd, Medi Caps Ltd, Welcure Drugs & Pharmaceuticals Ltd, Sunrest Lifescience Ltd, Chandra Bhagat Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹34.5 a share on 10 Jul 2026, Walpar Nutritions Ltd (WALPAR) was valued at a price-to-earnings ratio of 13.12x against an industry P/E of 36.41x and a price-to-book of 1.71x on a book value of ₹20.13 per share. Solomo computes return on equity of 13.09% and return on capital employed of 13.74% from filed results.
- P/E
- 13.12x
- Industry P/E
- 36.41x
- P/B
- 1.71x
- EPS (TTM)
- ₹2.64
- Book value / share
- ₹20.13
- ROE
- 13.09%
- ROCE
- 13.74%
- ROA
- 4.84%
- Debt / equity
- 0.89x
- Dividend yield
- 0%
- EBITDA margin
- 8.78%
- 52-week range
- ₹21.25 – ₹51.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Walpar Nutritions Ltd (WALPAR) reported revenue of ₹78.79 crore, net profit of ₹3 crore and earnings per share of ₹2.63. That compares with revenue of ₹71.76 crore and net profit of ₹2.79 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹42.3 crore and net profit ₹1.5 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 26.76 | 35.14 | 62.52 | 71.76 | 78.79 |
| Net profit (₹ cr) | 0.36 | 0.81 | 1.94 | 2.79 | 3 |
| EPS (₹) | 0.42 | 0.65 | 1.68 | 2.47 | 2.63 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 29.20% | 31.01% | 14.78% |
| Profit growth | 69.27% | 59.38% | 43.59% |
| Stock price CAGR | - | -4% | -28% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 68.82% of Walpar Nutritions Ltd (WALPAR). Market capitalisation was ₹32 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2021.
Largest disclosed public shareholders in Mar 2026: XTENDED BUSINESS REPORTING LIMITED 2.22%, DAKSHABEN ASHVINKUMAR SHAH 1.9%, CHAMPAKLAL AMRATLAL SHAH 1.38%, SHRI BAJRANGBALI ASHOK CONSTRUCTION PRIVATE LIMITED 1.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 68.82% | - | - | - | - |
| Sep 2025 | 68.61% | - | - | - | - |
| Mar 2025 | 68.52% | - | - | - | - |
| Sep 2024 | 68.44% | - | - | - | - |
| Mar 2024 | 71.23% | - | - | - | - |
| Sep 2023 | 71.46% | - | - | - | - |
| Mar 2023 | 70.54% | - | - | - | - |
| Sep 2022 | 70.58% | - | - | - | - |